Our latest articles
Asco 2023 – Commands leaves the door open for Geron
Full data from Reblozyl’s Commands study show limited activity in MDS patients without ringed sideroblasts – a boon for Geron.
Asco 2023 – Regeneron nips at Bristol’s heels in Lag3
Fianlimab continues to look like biopharma’s leading Lag3 asset, with activity in a new melanoma setting to boot.
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
PTC fails phase 3, and looks to a regulatory filing
Vatiquinone’s pivotal failure in Friedreich’s ataxia prompts a data dredge to come up with a regulatory package. And why not?
Novo makes a gene editing move
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Sanofi seeks to build on COPD win
Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.
Here come the PD-1 agonists
Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?
Scribe signs another big pharma deal
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
Spotlight – Few signs of gout pipeline flaring up
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
